ASCO 2023: Targeted Therapy for Early-Stage NSCLC

ASCO 2023: Targeted Therapy for Early-Stage NSCLC

Bibliographic Details
Main Author:	Roy Herbst
Format:	Article
Language:	English
Published:	THE HEALTHBOOK COMPANY LTD. 2023-06-01
Series:	healthbook TIMES. Oncology Hematology
Online Access:	https://doi.org/10.36000/hbT.OH.2023.16.113

Similar Items

ASCO 2023: Recent Progress in Lung Cancer Therapy
by: Charu Aggarwal
Published: (2023-06-01)

The Changing Landscape of Urothelial Carcinoma Therapy: Updates from ASCO GU 2023
by: Alex Friedlaender
Published: (2023-06-01)

Genitourinary cancers updates: highlights from ASCO 2023
by: Qian Qin, et al.
Published: (2023-11-01)

Recent Advances in Gynecological Malignancies: Focus on ASCO 2023
by: Olga Bodriagova, et al.
Published: (2023-09-01)

Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline
by: Ainhoa Costas-Chavarri, et al.
Published: (2019-02-01)

ASCO 2009
by: Cvetka Bilban-Jakopin
Published: (2009-12-01)

BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting
by: James F. Wu, et al.
Published: (2023-07-01)

ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
by: Tanja Cufer, et al.
Published: (2023-09-01)

Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium
by: Jiazheng Yu, et al.
Published: (2023-07-01)

Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
by: Jiangxue Hou, et al.
Published: (2023-08-01)

Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting
by: Katherine I. Zhou, et al.
Published: (2024-08-01)

ASCO Domestic Quality Programs
by: Issam Makhoul, et al.
Published: (2024-08-01)

Repetition and Distance in ASCO's fotonovelas
by: Paloma Checa Gismero
Published: (2024-09-01)

Advancing Ovarian Cancer Treatment: The Latest Insights on PARP Inhibitors from ASCO 2023
by: Yves van Roon, et al.
Published: (2023-12-01)

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting
by: Matthieu Roulleaux-Dugage, et al.
Published: (2023-08-01)

CD20 × CD3 bispecific antibodies for lymphoma therapy: latest updates from ASCO 2023 annual meeting
by: Xinyuan Liu, et al.
Published: (2023-08-01)

Aktivnosti največjega mednarodnega strokovnega združenja onkologov ASCO in pogled na srečanje ASCO 2011
by: Tanja Čufer
Published: (2011-12-01)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
by: Jiangxue Hou, et al.
Published: (2023-10-01)

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 Annual Meeting
by: Juanjuan Zhao, et al.
Published: (2023-08-01)

Analysis of outcomes in resected early-stage NSCLC with rare targetable driver mutations
by: Nadia Ghazali, et al.
Published: (2024-12-01)

Novel therapies in breast cancer: what is new from ASCO 2008
by: Lu Janice, et al.
Published: (2008-10-01)

The role of immunotherapy in early-stage and metastatic NSCLC
by: Attila Lieber, et al.
Published: (2024-07-01)

ASCO Global Guidelines: Methods and Opportunities
by: Zeba Aziz, et al.
Published: (2024-08-01)

Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects
by: Solange Peters, et al.
Published: (2022-07-01)

New treatments and trials for renal cell carcinoma: Latest updates from 2023 ASCO-GU Cancers Symposium
by: Yiqing Guo, et al.
Published: (2023-11-01)

Targeted therapeutic options in early and metastatic NSCLC-overview
by: Gabriella Gálffy, et al.
Published: (2024-03-01)

Highlights in Prostate Cancer from ASCO GU 2022
by: Alexander Meisel
Published: (2022-06-01)

Global Equity in Clinical Trials: An ASCO Policy Statement
by: Sana A. Al Sukhun, et al.
Published: (2024-03-01)

Interpretation on Management of Dyspnea in Advanced Cancer: ASCO Guideline
by: JIA Zhimeng, et al.
Published: (2024-01-01)

Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy
by: Lin JIANG, et al.
Published: (2022-07-01)

Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
by: Yuanhong Jiang, et al.
Published: (2023-08-01)

PET–CT for visualizing the pathophysiology of COPD in patients with early‐stage NSCLC
by: Haruki Kobayashi, et al.
Published: (2024-12-01)

Longitudinal Plasma ctDNA Testing in Resected Early-Stage NSCLC
by: J. Feng, et al.
Published: (2023-11-01)

Highlights in Renal Cell Carcinoma from ASCO GU 2022
by: Ursula Vogl
Published: (2022-06-01)

Melancolía, asco y lenguaje corporal en la anorexia
by: Elvia Mireya Ahedo Rodríguez
Published: (2010-01-01)

Latest therapeutic advances from the ASCO 2010 Annual Meeting
by: R. Charles Coombes, et al.
Published: (2010-11-01)

Electrochemical oxidation of the phospha‐ and arsaethynolate anions, PCO– and AsCO–
by: Tambornino, F, et al.
Published: (2019)

El asco: una emoción entre naturaleza y cultura
by: Eduardo Alberto León
Published: (2013-11-01)

Long-Term Survival and Failure Outcomes of Single-Fraction Stereotactic Body Radiation Therapy in Early Stage NSCLC
by: Austin J. Iovoli, MD, et al.
Published: (2023-12-01)

Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC
by: Jay M. Lee, MD, et al.
Published: (2023-04-01)